[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340278-105":59,"doc-detail-340278-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synergic-activity-of-fgfr2-and-mek-inhibitors-in-the-treatment-of-fgfr2-amplified-cancers-of-unknown-primary","Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary","","Patients with cancer of unknown primary (CUP) face aggressive disease and limited therapeutic access, making reliable preclinical models essential. Using ascites-derived tumor cells, two CUP cell lines (CUP#55, #96) and corresponding patient-derived xenografts were generated and thoroughly characterized. Tissue-of-origin predictions were supported by microRNA profiling and single-cell transcriptomics, while genomic and fluorescence in situ hybridization analyses identified FGFR2 amplification. Combined FGFR2 inhibition (BGJ398/ infigratinib) with MEK blockade (trametinib) showed strong synergic, in vitro and in vivo activity, with single-cell expression revealing tumor plasticity and enhanced epithelial-phenotype sensitivity, supporting rationale for personalized FGFR2–MEK targeting.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synergic-activity-of-fgfr2-and-mek-inhibitors-in-the-treatment-of-fgfr2-amplified-cancers-of-unknown-primary/340278/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synergic-activity-of-fgfr2-and-mek-inhibitors-in-the-treatment-of-fgfr2-amplified-cancers-of-unknown-primary/340278.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes cancers of unknown primary (CUP) difficult to treat?","Question",{"text":112,"@type":113},"CUP is associated with aggressive disease, late-stage diagnosis with existing metastases, and a limited ability to match therapy to a primary site, leading to poor outcomes with largely empirical treatments.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were FGFR2-amplified CUP models generated and validated?",{"text":117,"@type":113},"Two CUP cell lines (CUP#55 and #96) and corresponding patient-derived xenografts were derived from ascites tumor cells and then characterized using histological, immune-phenotypical, molecular, and genomic analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the FGFR2 plus MEK inhibitor combination important in this study?",{"text":121,"@type":113},"FGFR2 was identified as a main oncogenic driver, and combining the FGFR2-targeting drug BGJ398 (infigratinib) with the MEK inhibitor trametinib produced synergic and exceptionally active effects in vitro and in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340278,1790175632,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Original Article  \nSynergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-ampliﬁed cancers of unknown primary  \nAndrea Cavazzoni, 1, 12 Irene Salamon,2, 12 Claudia Fumarola, 1, 12 Giulia Gallerani,3 Noemi Laprovitera,2 Francesco Gelsomino,2 Mattia Riefolo,2,3 Karim Rihawi,2 Elisa Porcellini,3 Tania Rossi,4 Martina Mazzeschi,2 Maria Naddeo,2 Salvatore Serravalle,2 Elisabetta Broseghini,2 Federico Agostinis,5, 10 Olivier Deas,6  \nRoberta Roncarati,3,7 Giorgio Durante,3 Ilaria Pace,3 Mattia Lauriola,3 Ingrid Garajova,8 George A. Calin,9 Massimiliano Bonafè,2,3 Antonia D’Errico,2,3 Pier Giorgio Petronini, 1 Stefano Cairo,6, 11 Andrea Ardizzoni,2,3 Gabriele Sales,5, 13 and Manuela Ferracin2,3, 13  \n1Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy; 2IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy; 3Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy; 4Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola 47014, Italy; 5Department of Biology, University of Padova, 35031 Padua, Italy; 6XenTech, Evry 91100, France; 7Istituto di Genetica Molecolare “Luigi Luca Cavalli-Sforza” (IGM) - Consiglio Nazionale delle Ricerche (CNR), 40136 Bologna, Italy; 8Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy; 9Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \nPatients with cancer of unknown primary (CUP) carry the double burden of an aggressive disease and reduced access to therapies. Experimental models are pivotal for CUP biology investigation and drug testing. We derived two CUP cell lines (CUP\\#55 and \\#96) and corresponding patient-derived xenografts (PDXs), from ascites tumor cells. CUP cell lines and PDXs underwent histological, immune-phenotypical, molecular, and genomic characterization conﬁrming the features of the original tumor. The tissue-of-origin prediction was obtained from the tumor microRNA expression proﬁle and conﬁrmed by single-cell transcriptomics. Genomic testing and ﬂuorescence in situ hybridization analysis identiﬁed FGFR2 gene ampliﬁcation in both models, in the form of homogeneously staining region (HSR) in CUP\\#55 and double minutes in CUP\\#96. FGFR2 was recognized as the main oncogenic driver and therapeutic target. FGFR2-targeting drug BGJ398 (inﬁgratinib) in combination with the MEK inhibitor trametinib proved to be synergic and exceptionally active, both in vitro and in vivo. The effects of the combined treatment by single-cell gene expression analysis revealed a remarkable plasticity of tumor cells and the greater sensitivity of cells with epithelial phenotype. This study brings personalized therapy closer to CUP patients and provides the rationale for FGFR2 and MEK targeting in metastatic tumors with FGFR2 pathway activation.  \nINTRODUCTION  \nMetastases develop when tumor cells spread from the primary site to surrounding or distant tissues and are responsible for 90% of cancer-related deaths.1 Among metastatic patients, 3%–5% show no clinical evidence of a primary site at diagnosis. These cases  \nare classiﬁed as cancers of uncertain origin or cancers of unknown primary site (CUPs) or occult primary tumors.2,3 They are usually diagnosed at a late stage, with patients presenting one or more metastases already at the ﬁrst diagnosis. The identiﬁcation of the tumor primary site is usually obtained by a combination of diagnostic investigations including physical examinations, blood analyses, imaging, and immunohistochemical (IHC) testing of the tumor tissue. In CUP patients, these investigations are inconclusive.  \nInternational guidelines for tumor treatment are based on primary site indication. Therefore, CUP treatment requires a blind approach, which is very challenging for oncologists. Consequently, CUPs are typically treated with empiric platinum-based chemotherap","cbCaiqQxOs448geI","https://ap.wps.com/l/cbCaiqQxOs448geI","pdf",4969230,"English","# Introduction\n## Unmet needs in cancers of unknown primary\n## Limitations of current empiric treatment approaches\n## Rationale for molecular testing\n# Study approaches and characterization (cell lines and PDX models)","[{\"question\":\"What makes cancers of unknown primary (CUP) difficult to treat?\",\"answer\":\"CUP is associated with aggressive disease, late-stage diagnosis with existing metastases, and a limited ability to match therapy to a primary site, leading to poor outcomes with largely empirical treatments.\"},{\"question\":\"How were FGFR2-amplified CUP models generated and validated?\",\"answer\":\"Two CUP cell lines (CUP#55 and #96) and corresponding patient-derived xenografts were derived from ascites tumor cells and then characterized using histological, immune-phenotypical, molecular, and genomic analyses.\"},{\"question\":\"Why is the FGFR2 plus MEK inhibitor combination important in this study?\",\"answer\":\"FGFR2 was identified as a main oncogenic driver, and combining the FGFR2-targeting drug BGJ398 (infigratinib) with the MEK inhibitor trametinib produced synergic and exceptionally active effects in vitro and in vivo.\"}]","Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary | PDF",1790035481,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b121f14100e03d56b93c85325555be00.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f7e030d7047168e8fad8f5318392013.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abc1d5a6cebcd2893bafe3f55c4fefd3.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b92f64782d749ea6eef5abfb824483c.webp",980,1272]